Genome & Company (XKON:A314130) announced a private placement of 1,33,334 convertible preferred shares at a price of KRW 30,000 for gross proceeds of KRW 4,000,020,000 on June 17, 2020. The transaction included participation from Activation of KB KONEX Investment union for 116,667 shares Fortuna Investment Co., Ltd for 16,667 shares .The funding is being raised through third party allotment method. The transaction has been approved by the board of directors of the company. The transaction is expected to close on June 25, 2020. The preferred shares are convertible in to common shares during the period from June 26, 2020 to June 26, 2030.